The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients

Abstract Background BRAF mutations occur in 2–4% non-small cell lung cancer (NSCLC) patients and can be categorized into three functional classes based on signaling mechanism and kinase activity: RAS-independent kinase-activating V600 monomers (class 1), RAS-independent kinase-activating dimers (cla...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Journal of Translational Medicine
المؤلفون الرئيسيون:	Quan Lin, Haoran Zhang, Huaxin Ding, Jun Qian, Analyn Lizaso, Jing Lin, Han Han-Zhang, Jianxing Xiang, Yuping Li, Hong Zhu
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	BMC 2019-08-01
الموضوعات:	BRAF Non-small cell lung cancer Chinese
الوصول للمادة أونلاين:	http://link.springer.com/article/10.1186/s12967-019-2036-7

مواد مشابهة

Treatment with BRAF/MEK: inhibitors in mutant BRAF V600E papillary craniopharyngioma
حسب: Eva Marie Erfurth, وآخرون
منشور في: (2024-12-01)

Case report: BRAF-inhibitor therapy in BRAF-mutated primary CNS tumours including one case of BRAF-mutated Rosai-Dorfman disease
حسب: Christopher Cronin, وآخرون
منشور في: (2022-12-01)

Braf protein mutation and its significancy within patients with melanoma
حسب: Julia Kuchnicka, وآخرون
منشور في: (2022-08-01)

Surrogate to predict overall survival in patients with BRAF V600E-mutant colorectal cancer treated with BRAF inhibitor combinations
حسب: J. Ros, وآخرون
منشور في: (2025-09-01)

Recognition of BRAF by CDC37 and Re-Evaluation of the Activation Mechanism for the Class 2 BRAF-L597R Mutant
حسب: Dennis M. Bjorklund, وآخرون
منشور في: (2022-06-01)

BRAF mutation in colorectal cancer: An update
حسب: Colombo Alfredo, وآخرون
منشور في: (2023-01-01)

Clinicopathological relevance of BRAF and SMO mutations in Chinese patients with ameloblastoma
حسب: Chen Ruixue, وآخرون
منشور في: (2023-12-01)

Braf-Mutant Melanomas: Biology and Therapy
حسب: Elvira Pelosi, وآخرون
منشور في: (2024-12-01)

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing
حسب: Gulietta M. Pupo, وآخرون
منشور في: (2017-05-01)

BRAF V600E mutation in thyroid carcinoma: a large-scale study in Han Chinese population
حسب: Rong Cong, وآخرون
منشور في: (2024-09-01)

Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
حسب: Tiziana Notarangelo, وآخرون
منشور في: (2017-10-01)

PROMISES FOR TREATING COLON CANCER PATIENTS WITH BRAF GENE MUTATION
حسب: M. Yu. Fedyanin, وآخرون
منشور في: (2015-02-01)

Hyperplastic Polyposis Syndrome Identified with a BRAF Mutation
منشور في: (2012-04-01)

Crizotinib resistance: BRAF mutation implications for therapeutic strategies
حسب: Li Xie
منشور في: (2021-01-01)

Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive <i>BRAF</i> Mutant Advanced Melanoma
حسب: Ernesto Rossi, وآخرون
منشور في: (2023-01-01)

The clinical and genomic distinctions of Class1/2/3 BRAF-mutant colorectal cancer and differential prognoses
حسب: Yungchang Chen, وآخرون
منشور في: (2023-01-01)

Real-world occurrence, therapy, and outcome of patients with class 2 or 3 BRAF compared with class 1 BRAF-mutated cancers
حسب: S. Pradervand, وآخرون
منشور في: (2024-12-01)

Clinical significance of <it>BRAF </it>mutations in metastatic melanoma
حسب: Polsky David, وآخرون
منشور في: (2004-12-01)

Association between braf gene mutation status and clinical-morphological features of cutaneous melanoma
حسب: O. I. Kit, وآخرون
منشور في: (2016-06-01)

Case report: Metastatic BRAF V600E–mutated adult Wilms’ tumor with robust response to BRAF/MEK inhibitor therapy
حسب: Matthew R. Kroll, وآخرون
منشور في: (2024-07-01)

Evolution of Acquired Drug Resistance in BRAF-Mutant Melanoma
حسب: Josué Ballesteros-Álvarez, وآخرون
منشور في: (2024-10-01)

Prospects of BRAF/MEK Inhibitor Therapy in Papillary Craniopharyngiomas with the BRAF V600E Mutation: A Scoping Review
حسب: Shingo FUJIO, وآخرون
منشور في: (2025-05-01)

Therapeutic strategies for BRAF mutation in non-small cell lung cancer: a review
حسب: Megha Puri, وآخرون
منشور في: (2023-08-01)

Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors
حسب: Lovisa Falkman, وآخرون
منشور في: (2024-04-01)

High BRAF V600 Mutation Level Associated with Worse Outcome in Metastatic Melanoma Patients Receiving BRAF and MEK Inhibitors
حسب: Ariane Fizazi, وآخرون
منشور في: (2024-11-01)

BRAF mutation in hairy cell leukemia
حسب: Ahmad Ahmadzadeh, وآخرون
منشور في: (2014-09-01)

Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancer
حسب: Eunyoung Tak, وآخرون
منشور في: (2025-03-01)

Beneficial effects of vemurafenib on craniopharyngioma carrying BRAF-V600E mutation
حسب: WANG Xi, YE Ting, NIE Min, WU Xueyan, MAO Jiangfeng
منشور في: (2024-06-01)

Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer
حسب: Elisa Grassi, وآخرون
منشور في: (2021-06-01)

High frequency of BRAF mutations in primary mucinous ovarian carcinoma of Taiwanese patients
حسب: Wan-Ru Chao, وآخرون
منشور في: (2021-11-01)

The phenomenon of the BRAF and TERTp mutational duet in melanoma and other cancers
حسب: Dagmara Rusinek, وآخرون
منشور في: (2024-12-01)

Novel BRAF N581S mutation in mantle cell lymphoma
حسب: Nisha Hariharan, وآخرون
منشور في: (2024-02-01)

DETECTION OF SOMATIC MUTATIONS IN THE BRAF GENE BY PYROSEQUENCING
حسب: O. P. Dribnokhodova, وآخرون
منشور في: (2021-10-01)

Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation
حسب: Yukiko Kiniwa, وآخرون
منشور في: (2021-03-01)

A novel GIT2-BRAF fusion in pilocytic astrocytoma
حسب: Jeffrey Helgager, وآخرون
منشور في: (2017-11-01)

Landscape of BRAF transcript variants in human cancer
حسب: Maurizio S. Podda, وآخرون
منشور في: (2025-09-01)

Inhibitors of pan PI3K signaling synergize with BRAF or MEK inhibitors to prevent BRAF-mutant melanoma cell growth
حسب: Melanie eSweetlove, وآخرون
منشور في: (2015-06-01)

Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications
حسب: Irene Vanni, وآخرون
منشور في: (2020-07-01)

A large‐scale, multicenter characterization of BRAF G469V/A‐mutant non‐small cell lung cancer
حسب: Han Wu, وآخرون
منشور في: (2024-05-01)

Real‐world treatment and outcomes of patients with metastatic BRAF mutant colorectal cancer
حسب: Ting Xu, وآخرون
منشور في: (2023-05-01)